HOME >> BIOLOGY >> NEWS
Fossil discovery marks earliest record of limbloss in ancient lizard

ample of paleontological data being used to elucidate the potential molecular genetic causes of a major evolutionary transition, said Dr. Martin Cohn, from the Department of Zoology and University of Florida Genetics Institute.

"This is a terrifically important discovery because it shows, in a group of animals thought to be closely related to snakes, that forelimb reduction and trunk elongation were well underway before the onset of hindlimb reduction," said Cohn. "By uncovering the sequence of the morphological changes that occurred during evolution of a snake-like body plan, Palci and Caldwell's study provides important clues as to which developmental mechanisms could have been involved."

The researchers think this snake-like lizard was about 10 to 12 inches long, had a small head perched on an elongated neck, body and tail and relatively large and well-developed rear limbs. All bones of the forearm, including the hands and digits were not formed during development.

"For some oddball reason the forelimbs were lost before the rear limbs when you would think it would be the opposite," said Caldwell. "The front limbs would be useful for holding onto dinner or digging a hole but it must be developmentally easier to get rid of the forelimbs."

The most well known ancient fossil snakes also kept their hind limbs. Living lizards also show almost every variation in limb reduction from a perfectly formed back limb with no forelimb, or a spike for a forelimb and one or two toes on the rearlimb, to total limblessness. This degree of variation makes it very difficult to understand the pattern of evolutionary limb loss in these animals.

"This discovery is one more data point that might help us answer some questions and perhaps shed some light on the fin to limb transition, which is a key step in the evolution of land animals," said Caldwell. "It doesn't give us all the answers but it's a start."


'"/>

Contact: Phoebe Dey
phoebe.dey@ualberta.ca
780-492-0437
University of Alberta
22-Mar-2007


Page: 1 2 3

Related biology news :

1. Fossil DNA illuminates life
2. Fossils of ancient sea monster found in Montana
3. Fossil is missing link in elephant lineage
4. Fossilized liquid assembly: Nanomaterials research tool
5. Fossils pinpoint tropics as Earths most fruitful biodiversity spawning ground
6. Early bird caught the fish: Fossils depict aquatic origins of birds 115 million years ago
7. Fossil wood gives vital clues to ancient climates
8. Fossils tell the hole story of killer drillers and their prey
9. Fossil Patagonian plants show high insect feeding diversity 52 million years ago
10. Fossil records show biodiversity comes and goes
11. Enzyme discovery sheds light on vitamin D

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Fossil discovery marks earliest record limbloss ancient lizard

(Date:12/10/2014)... 08, 2014 Research and Markets ... the "Biometrics Market in Japan 2014-2018" ... http://photos.prnewswire.com/prnh/20130307/600769 The integration of ... rural banking and upgradation of the driver,s license ... the market. Besides the aforementioned projects, biometrics is ...
(Date:12/5/2014)... 2014 Increased emphasis on product quality, ... testing and inspection technologies. The convergence of industries ... range of innovative test solutions. This trend is ... which is generally more inclined towards communication, media ... strategies of test equipment vendors will cater to ...
(Date:12/4/2014)... 3, 2014  Crossmatch™, a leading provider of ... DigitalPersona ® Pro Enterprise software and U.are.U ... throughout First Bank branch locations in ... and Virginia. First Bank, a progressive community ... North Carolina , selected the Crossmatch biometrics-based ...
Breaking Biology News(10 mins):Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3
(Date:12/19/2014)... YORK , Dec. 18, 2014 Relmada ... therapies for the treatment of chronic pain, announced the ... today. "This was a transformational year in ... promising future for our company," said Sergio Traversa ... year, we have executed on key financial, human resource ...
(Date:12/17/2014)... N.J. (PRWEB) December 17, 2014 ... (Euronext: IPN; ADR: IPSEY), today announced ... (referred to as Somatuline®) was approved by the ... treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in adult ... advanced or metastatic disease to improve progression-free survival ...
(Date:12/17/2014)... 17, 2014 Audacity, a leading California-based ... member of the Huntsworth Health Group, is proud to ... team. In her role, Gonzales will serve as Senior ... incredibly honored to welcome a talent of Jamie’s caliber ... Gaëtan Fraikin. “She is a proven healthcare innovation leader ...
(Date:12/17/2014)... Mass. , Dec. 17, 2014   Synageva ... biopharmaceutical company developing therapeutic products for rare disorders, announced ... Conference being held in San Francisco, CA. ... President and Chief Executive Officer, will present on Monday, ... EST).  The presentation will be webcast live and may ...
Breaking Biology Technology:Relmada Therapeutics Announces Results of Annual Shareholders Meeting 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 5Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 6Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 7Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 8Audacity Welcomes Healthcare Communications Expert Jamie Gonzales as Senior Vice President of Client Services 2
Cached News: